A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and Treatment

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

(2022) Wanwisa Dejnirattisai et al.   CELL

Omicron variant escapes therapeutic mAbs including recently released Evusheld ®, contrary to eight prior main VOC

(2022) Céline Boschi et al.   CLINICAL INFECTIOUS DISEASES

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

(2022) Yunlong Cao et al.   NATURE

Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2

(2022) Lihong Liu et al.   NATURE

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies

(2022) Laura A. VanBlargan et al.   NATURE MEDICINE

Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant

(2022) Emi Takashita et al.   NEW ENGLAND JOURNAL OF MEDICINE

The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in non-human primates and has an extended half-life in humans

(2022) Yueh-Ming Loo et al.   Science Translational Medicine

Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies

(2022) Robert Stuver et al.   CANCER CELL

Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies

(2022) Timothée Bruel et al.   NATURE MEDICINE

Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19

(2022) Myron J. Levin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2

(2022) Emi Takashita et al.   NEW ENGLAND JOURNAL OF MEDICINE

In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B.1.1.529 isolate

(2022) Franck Touret et al.   Scientific Reports

Tixagevimab/cilgavimab pre‐exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave

(2022) Ayman Al Jurdi et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Correlates of protection against SARS ‐ CoV ‐2 infection and COVID‐19 disease

(2022) David Goldblatt et al.   IMMUNOLOGICAL REVIEWS

Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies

(2022) Daichi Yamasoba et al.   LANCET INFECTIOUS DISEASES

Monoclonal antibody therapies against SARS-CoV-2

(2022) Daniele Focosi et al.   LANCET INFECTIOUS DISEASES

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection

(2022) Yunlong Cao et al.   NATURE

Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains

(2022) James Brett Case et al.   Nature Communications

In vitro activity of therapeutic antibodies against SARS-CoV-2 Omicron BA.1, BA.2 and BA.5

(2022) Franck Touret et al.   Scientific Reports

Covid-19: UK will not buy Evusheld owing to “insufficient data” on protection, government says

(2022) Elisabeth Mahase   BMJ-British Medical Journal

Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial

(2022) Hugh Montgomery et al.   Lancet Respiratory Medicine

Prescription of Anti-Spike Monoclonal Antibodies in COVID-19 Patients with Resistant SARS-CoV-2 Variants in Italy

(2022) Daniele Focosi et al.   Pathogens

Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75

(2022) Qian Wang et al.   Cell Host & Microbe

Myalgia in liver transplant recipients after receiving tixagevimab/cilgavimab for pre‐exposure prophylaxis of COVID‐19: A case series

(2022) Hanna L. Kleiboeker et al.   Transplant Infectious Disease

Qualification of a Biolayer Interferometry Assay to Support AZD7442 Resistance Monitoring

(2022) Tyler Brady et al.   Microbiology Spectrum

Administration of Anti–SARS-CoV-2 Monoclonal Antibodies After US Food and Drug Administration Deauthorization

(2022) Timothy S. Anderson et al.   JAMA Network Open

Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies

(2021) Maxwell T. Finkelstein et al.   Viruses-Basel

Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7

(2021) Pengfei Wang et al.   NATURE

Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization

(2021) Pengfei Wang et al.   Cell Host & Microbe

Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma

(2021) Harini Natarajan et al.   mBio

The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies

(2021) Richard Copin et al.   CELL

Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail

(2021) Jinhui Dong et al.   Nature Microbiology

Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding

(2020) Tyler N. Starr et al.   CELL

Safety, Tolerability, and Pharmacokinetics of MEDI8897, an Extended Half-Life Single-Dose Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants

(2018) Joseph B. Domachowske et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults

(2013) Gabriel J. Robbie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY